1-18 of 18
Meredith M. Regan
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract 3707: Characterization of estrogen receptor expression on CTCs during CDK4/6i treatment in HR+/HER2- metastatic breast cancer: Results from the PACE phase II study

Mara Serena Serafini, Carolina Reduzzi, Lorenzo Gerratana, Rinath Jeselsohn, Reshma L. Mahtani, Cynthia X. Ma, Angela DeMichele, Jane Lowe Meisel, Kathy D. Miller, Yara Abdou, Elizabeth C. Riley, Rubina Qamar, Priyanka Sharma, Sonya Reid, Harold J. Burstein, Sara M. Tolaney, Michelle K. DeMeo, Yuan Liu, Eric Gauthier, Yue Ren, Meredith M. Regan, Huiping Liu, Erica L. Mayer, Massimo Cristofanilli
Journal: Cancer Research
Cancer Res (2024) 84 (6_Supplement): 3707.
https://doi.org/10.1158/1538-7445.AM2024-3707
Published: 22 March 2024
View article titled, Abstract 3707: Characterization of estrogen receptor expression on CTCs during CDK4/6i treatment in HR+/HER2- metastatic breast cancer: Results from the PACE phase II study
Journal Articles

Abstract GS2-04: Aromatase inhibitors versus tamoxifen in pre-menopausal women with estrogen receptor positive early stage breast cancer treated with ovarian suppression: A patient level meta-analysis of 7,030 women in four randomised trials

Rosie Bradley, Jeremy Braybrooke, Richard Gray, Robert K Hills, Zulian Lui, Hongchao Pan, Richard Peto, Jonas Bergh, Sandra M Swain, Prudence Francis, Michael Gnant, Francesco Perrone, Meredith M Regan
Journal: Cancer Research
Cancer Res (2022) 82 (4_Supplement): GS2-04.
https://doi.org/10.1158/1538-7445.SABCS21-GS2-04
Published: 15 February 2022
View article titled, Abstract GS2-04: Aromatase inhibitors versus tamoxifen in pre-menopausal women with estrogen receptor positive early stage breast cancer treated with ovarian suppression: A patient level meta-analysis of 7,030 women in four randomised trials
Journal Articles

Abstract P2-12-18: A phase 2 study of neoadjuvant systemic therapy with eribulin followed by doxorubicin and cyclophosphamide for HER2-negative inflammatory breast cancer

Filipa Lynce, Eren D. Yeh, Meredith M. Regan, Lei Qin, Camden P. Bay, Ian Krop, Beth T Harrison, Faina Nakhlis, Jennifer Bellon, Beth Overmoyer
Journal: Cancer Research
Cancer Res (2022) 82 (4_Supplement): P2-12-18.
https://doi.org/10.1158/1538-7445.SABCS21-P2-12-18
Published: 15 February 2022
View article titled, Abstract P2-12-18: A phase 2 study of neoadjuvant systemic therapy with eribulin followed by doxorubicin and cyclophosphamide for HER2-negative inflammatory breast cancer
Journal Articles

Abstract GS2-05: Randomized comparison of adjuvant aromatase inhibitor exemestane (E) plus ovarian function suppression (OFS) vs tamoxifen (T) plus OFS in premenopausal women with hormone receptor-positive (HR+) early breast cancer (BC): update of the combined TEXT and SOFT trials

Meredith M Regan, Barbara A Walley, Gini F Fleming, Prudence A Francis, Marco A Colleoni, István Láng, Henry L Gómez, Carlo A Tondini, Harold J Burstein, Matthew P Goetz, Eva M Ciruelos, Vered Stearns, Hervé R Bonnefoi, Silvana Martino, Charles E Geyer, Jr, Claudio Chini, Alessandro M Minisini, Simon Spazzapan, Thomas Ruhstaller, Eric P Winer, Barbara Ruepp, Sherene Loi, Alan S Coates, Aron Goldhirsch, Richard D Gelber, Olivia Pagani
Journal: Cancer Research
Cancer Res (2022) 82 (4_Supplement): GS2-05.
https://doi.org/10.1158/1538-7445.SABCS21-GS2-05
Published: 15 February 2022
View article titled, Abstract GS2-05: Randomized comparison of adjuvant aromatase inhibitor exemestane (E) plus ovarian function suppression (OFS) vs tamoxifen (T) plus OFS in premenopausal women with hormone receptor-positive (HR+) early breast cancer (BC): update of the combined TEXT and SOFT trials
Journal Articles

Abstract OT-23-03: Pre- versus sub-pectoral implant-based breast reconstruction after skin-sparing mastectomy or nipple-sparing mastectomy (OPBC-02 PREPEC): A pragmatic, multicenter, randomized, superiority trial

Walter Paul Weber, Elisabeth A Kappos, Meredith M Regan, Giusi Moffa, Yves Harder, Karin Ribi, Shelley Potter, Andrea Pusic, Mathias K Fehr, Lars G Hemkens, Thomas Holzbach, Jian Farhadi, Colin Simonson, Michael Knauer, Ralph Verstappen, Heiner Bucher, Daniel Zwahlen, Frank Zimmermann, Matthias Schwenkglenks, Rosine Mucklow, Vesna Bjelic-Radisic, Amelia Chiorescu, Yoon Chun, Subrina Farah, Xiasong Chen, Linda Nigard, Sherko Kümmel, Roland Reitsamer, Maik Hauschild, Ilario Fulco, Christoph Tausch, Thomas Fischer, Dimitri Sarlos, Mihai Constantinescu, Judith E Lupatsch, Florian Fitzal, Joerg Heil, Zoltán Mátrai, Jana de Boniface, Christian Kurzeder, Martin Haug, Alexandra Schulz
Journal: Cancer Research
Cancer Res (2021) 81 (4_Supplement): OT-23-03.
https://doi.org/10.1158/1538-7445.SABCS20-OT-23-03
Published: 15 February 2021
View article titled, Abstract OT-23-03: Pre- versus sub-pectoral implant-based breast reconstruction after skin-sparing mastectomy or nipple-sparing mastectomy (OPBC-02 PREPEC): A pragmatic, multicenter, randomized, superiority trial
Journal Articles

Abstract OT-26-02: Phase III open-label, multicenter, randomized trial of adjuvant palbociclib in combination with endocrine therapy versus endocrine therapy alone for patients with hormone receptor-positive / HER2-negative resected isolated locoregional recurrence of breast cancer - The POLAR Trial

Elisabetta Munzone, Stefan Aebi, Noelia Martínez Jañez, Uwe Güth, Meritxell Bellet, Barbara Pistilli, Marija Balic, Heidi Roschitzki-Voser, Meredith M Regan
Journal: Cancer Research
Cancer Res (2021) 81 (4_Supplement): OT-26-02.
https://doi.org/10.1158/1538-7445.SABCS20-OT-26-02
Published: 15 February 2021
View article titled, Abstract OT-26-02: Phase III open-label, multicenter, randomized trial of adjuvant palbociclib in combination with endocrine therapy versus endocrine therapy alone for patients with hormone receptor-positive / HER2-negative resected isolated locoregional recurrence of breast cancer - The POLAR Trial
Journal Articles

Abstract GS4-08: Clinical utility of repeated circulating tumor cell (CTC) enumeration as early treatment monitoring tool in metastatic breast cancer (MBC) - a global pooled analysis with individual patient data

Wolfgang J Janni, Tracy C. Yab, Daniel F. Hayes, Massimo Cristofanilli, Francois-Clement Bidard, Michail Ignatiadis, Meredith M. Regan, Catherine Alix-Panabières, William E. Barlow, Carlos Caldas, Lisa A. Carey, Luc Dirix, Tanja Fehm, Jose A. Garcia-Saenz, Paola Gazzaniga, Daniele Generali, Lorenzo Gerratana, Rafael Gisbert-Criado, William Jacot, Zefei Jiang, Evi Lianidou, Mark J.M. Magbanua, Luis Manso, Dimitrios Mavroudis, Volkmar Müller, Elisabetta Munzone, Klaus Pantel, Jean-Yves Pierga, Brigitte Rack, Sabine Riethdorf, Hope S. Rugo, Kostandinos Sideras, Stefan Sleijfer, Jeffrey Smerage, Justin Stebbing, Leon W.M.M. Terstappen, José Vidal-Martínez, Rita Zamarchi, Karthik Giridhar, Thomas W.P. Friedl, Minetta C. Liu
Journal: Cancer Research
Cancer Res (2021) 81 (4_Supplement): GS4-08.
https://doi.org/10.1158/1538-7445.SABCS20-GS4-08
Published: 15 February 2021
View article titled, Abstract GS4-08: Clinical utility of repeated circulating tumor cell (CTC) enumeration as early treatment monitoring tool in metastatic breast cancer (MBC) - a global pooled analysis with individual patient data
Journal Articles

Abstract OT-28-02: Phase II randomized trial of neoadjuvant trastuzumab and pertuzumab with either palbociclib plus letrozole or paclitaxel for postmenopausal women with estrogen receptor-positive / HER2-positive breast cancer - The TOUCH trial

Laura Biganzoli, Etienne Brain, Luca Malorni, Andrea Gombos, Ursula Hasler-Strub, Claudio Zamagni, Camille Chakiba, Heidi Roschitzki-Voser, Meredith M Regan
Journal: Cancer Research
Cancer Res (2021) 81 (4_Supplement): OT-28-02.
https://doi.org/10.1158/1538-7445.SABCS20-OT-28-02
Published: 15 February 2021
View article titled, Abstract OT-28-02: Phase II randomized trial of neoadjuvant trastuzumab and pertuzumab with either palbociclib plus letrozole or paclitaxel for postmenopausal women with estrogen receptor-positive / HER2-positive breast cancer - The TOUCH trial
Journal Articles

Abstract PD13-06: Incidence and management of central nervous system metastases in patients with inflammatory breast cancer

Laura Warren, Samuel M Niman, Marie Claire Remolano, Jean Landry, Faina Nakhlis, Jennifer R Bellon, Meredith M Regan, Beth A Overmoyer
Journal: Cancer Research
Cancer Res (2021) 81 (4_Supplement): PD13-06.
https://doi.org/10.1158/1538-7445.SABCS20-PD13-06
Published: 15 February 2021
View article titled, Abstract PD13-06: Incidence and management of central nervous system metastases in patients with inflammatory breast cancer
Journal Articles

Abstract PD2-09: The role of CYP2D6 mediated tamoxifen metabolism in the suppression of ovarian function trial (SOFT)

Matthew P. Goetz, Gini F. Fleming, Mary Kuffel, John R. Hawse, John L. Black, Richard Weinshilboum, James N. Ingle, Patrizia dell’Orto, Olivia Biasi, Roswitha Kammler, Sherene Loi, Marco Colleoni, Giuseppe Viale, Prudence A Francis, Meredith M Regan
Journal: Cancer Research
Cancer Res (2021) 81 (4_Supplement): PD2-09.
https://doi.org/10.1158/1538-7445.SABCS20-PD2-09
Published: 15 February 2021
View article titled, Abstract PD2-09: The role of CYP2D6 mediated tamoxifen metabolism in the suppression of ovarian function trial (SOFT)
Journal Articles

Abstract PS5-05: Serum thymidine kinase activity in patients with luminal metastatic breast cancer treated with palbociclib and fulvestrant within the PYTHIA trial

Luca Malorni, Svitlana Tyekucheva, Florentine S Hilbers, Michail Ignatiadis, Patrick Neven, Marco Colleoni, Stéphanie Henry, Alberto Ballestrero, Andrea Bonetti, Guy Jerusalem, Konstantinos Papadimitriou, Antonio Bernardo, Francois Duhoux, Iain MacPherson, Alastair Thomson, David Mark Davies, Mattias Bergqvist, Matteo Benelli, Amelia McCartney, Heidi De Swert, Barbara Ruepp, Manuela Rabaglio, Rudolf Maibach, Martine Piccart, Meredith M Regan
Journal: Cancer Research
Cancer Res (2021) 81 (4_Supplement): PS5-05.
https://doi.org/10.1158/1538-7445.SABCS20-PS5-05
Published: 15 February 2021
View article titled, Abstract PS5-05: Serum thymidine kinase activity in patients with luminal metastatic breast cancer treated with palbociclib and fulvestrant within the PYTHIA trial
Journal Articles

Abstract 4207: Androgen receptor expression and ER+ breast cancer prognosis in the BIG 1-98 trial

Kevin H. Kensler, Meredith M. Regan, Yujing J. Heng, Michael E. Pyle, Stuart J. Schnitt, Beat Thürlimann, Giuseppe Viale, Marco Colleoni, Myles Brown, Rulla M. Tamimi
Journal: Cancer Research
Cancer Res (2018) 78 (13_Supplement): 4207.
https://doi.org/10.1158/1538-7445.AM2018-4207
Published: 01 July 2018
View article titled, Abstract 4207: Androgen receptor expression and ER+ breast cancer prognosis in the BIG 1-98 trial
Journal Articles

Abstract S3-08: Randomized comparison of adjuvant tamoxifen (T) plus ovarian function suppression (OFS) versus tamoxifen in premenopausal women with hormone receptor-positive (HR+) early breast cancer (BC): Analysis of the SOFT trial

Aron Goldhirsch, Richard D Gelber, Prudence A Francis, Meredith M Regan, Gini F Fleming, Istvan Lang, Eva M Ciruelos, Meritxell Bellet, Herve Bonnefoi, Miguel A Climent, Lorenzo Pavesi, Harold J Burstein, Silvana Martino, Nancy E Davidson, Charles E Geyer, Jr, Barbara A Walley, Robert E Coleman, Pierre Kerbrat, Manuela Rabaglio-Poretti, Alan S Coates
Journal: Cancer Research
Cancer Res (2015) 75 (9_Supplement): S3-08.
https://doi.org/10.1158/1538-7445.SABCS14-S3-08
Published: 01 May 2015
View article titled, Abstract S3-08: Randomized comparison of adjuvant tamoxifen (T) plus ovarian function suppression (OFS) versus tamoxifen in premenopausal women with hormone receptor-positive (HR+) early breast cancer (BC): Analysis of the SOFT trial
Journal Articles

Abstract S3-09: Patient-reported endocrine symptoms, sexual functioning and quality of life (QoL) in the IBCSG SOFT trial: Adjuvant treatment with tamoxifen (T) alone versus tamoxifen plus ovarian function suppression (OFS) in premenopausal women with hormone receptor-po

Karin Ribi, Weixiu Luo, Juerg Bernhard, Prudence A Francis, Meritxell Bellet, Harold J Burstein, Lorenzo Pavesi, Vani Parmar, Carlo Tondini, Marilena Visini, Roberto Torres, Per Karlsson, Simon Spazzapan, Antoni Avella, Thomas Ruhstaller, Fabio Puglisi, Meredith M Regan, Alan S Coates, Richard D Gelber, Gini F Fleming
Journal: Cancer Research
Cancer Res (2015) 75 (9_Supplement): S3-09.
https://doi.org/10.1158/1538-7445.SABCS14-S3-09
Published: 01 May 2015
View article titled, Abstract S3-09: Patient-reported endocrine symptoms, sexual functioning and quality of life (QoL) in the IBCSG SOFT trial: Adjuvant treatment with tamoxifen (T) alone versus tamoxifen plus ovarian function suppression (OFS) in premenopausal women with hormone receptor-po
Journal Articles

Abstract P4-18-03: IBCSG BIG 1-98 study: The long-term follow-up experience

Anita Giobbie-Hurder, Beat Thürlimann, Bent Ejlertsen, Patrick Neven, Robert E Coleman, Ian Smith, Andrew M Wardley, István Láng, Marco Colleoni, Marc Debled, John F Forbes, Karen N Price, Meredith M Regan, Manuela Rabaglio, Aron Goldhirsch, Alan S Coates, Richard D Gelber
Journal: Cancer Research
Cancer Res (2015) 75 (9_Supplement): P4-18-03.
https://doi.org/10.1158/1538-7445.SABCS14-P4-18-03
Published: 01 May 2015
View article titled, Abstract P4-18-03: IBCSG BIG 1-98 study: The long-term follow-up experience
Journal Articles

Abstract P1-12-06: Co-SOFT: The cognitive function substudy of the suppression of ovarian function trial (SOFT)

Kelly-Anne Phillips, Yang Feng, Karin Ribi, Jürg Bernhard, Fabio Puglisi, Meritxell Bellet, Simon Spazzapan, Per Karlsson, Daniel R Budman, Khalil Zaman, Ehtesham A Abdi, Susan M Domchek, Meredith M Regan, Alan S Coates, Richard D Gelber, Paul Maruff, Frances Boyle, John F Forbes, Gini F Fleming, Prudence A Francis
Journal: Cancer Research
Cancer Res (2015) 75 (9_Supplement): P1-12-06.
https://doi.org/10.1158/1538-7445.SABCS14-P1-12-06
Published: 01 May 2015
View article titled, Abstract P1-12-06: Co-SOFT: The cognitive function substudy of the suppression of ovarian function trial (SOFT)
Journal Articles

Abstract P1-12-01: CYP19A1 and ESR1 polymorphisms and selected early-onset side effects during combined endocrine therapy in the IBCSG TEXT trial for premenopausal women with hormone receptor-positive (HR+) early breast cancer

Harriet Johansson, Kathryn P Gray, Olivia Pagani, Meredith M Regan, Giuseppe Viale, Valentina Aristarco, Debora Macis, Antonella Puccio, Susanne Roux, Rudolf Maibach, Marco Colleoni, Manuela Rabaglio-Poretti, Alan S Coates, Richard D Gelber, Aron Goldhirsch, Roswitha Kammler, Bernardo Bonanni, Barbara A Walley
Journal: Cancer Research
Cancer Res (2015) 75 (9_Supplement): P1-12-01.
https://doi.org/10.1158/1538-7445.SABCS14-P1-12-01
Published: 01 May 2015
View article titled, Abstract P1-12-01: CYP19A1 and ESR1 polymorphisms and selected early-onset side effects during combined endocrine therapy in the IBCSG TEXT trial for premenopausal women with hormone receptor-positive (HR+) early breast cancer
Journal Articles

Evaluation of the 8q24 Prostate Cancer Risk Locus and MYC Expression

Mark M. Pomerantz, Christine A. Beckwith, Meredith M. Regan, Stacia K. Wyman, Gyorgy Petrovics, Yongmei Chen, Dorota J. Hawksworth, Fredrick R. Schumacher, Lorelei Mucci, Kathryn L. Penney, Meir J. Stampfer, Jennifer A. Chan, Kristin G. Ardlie, Brian R. Fritz, Rachael K. Parkin, Daniel W. Lin, Michelle Dyke, Paula Herman, Steve Lee, William K. Oh, Philip W. Kantoff, Muneesh Tewari, David G. McLeod, Shiv Srivastava, Matthew L. Freedman
Journal: Cancer Research
Cancer Res (2009) 69 (13): 5568–5574.
https://doi.org/10.1158/0008-5472.CAN-09-0387
Published: 01 July 2009
View article titled, Evaluation of the 8q24 Prostate Cancer Risk Locus and <em>MYC</em> Expression
Open the PDF for Evaluation of the 8q24 Prostate Cancer Risk Locus and <em>MYC</em> Expression in another window
Includes: Supplementary data